Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy. - Wikidata - awgldk - TriplyDB

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

http://www.wikidata.org/entity/Q34674995

about

Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance Docetaxel does not impair skeletal muscle force production in a murine model of cancer chemotherapy Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects.TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.Effects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle.Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPk signalling in skeletal muscle.The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle.Reciprocal dihydropyridine and ryanodine receptor interactions in skeletal muscle activation.Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma Targeted overexpression of mitochondrial catalase protects against cancer chemotherapy-induced skeletal muscle dysfunction.Mitochondria dysfunction in lung cancer-induced muscle wasting in C2C12 myotubes.Diagnostic ultrasound imaging of mouse diaphragm function Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy.Effects of endurance exercise and doxorubicin on skeletal muscle myogenic regulatory factor expression.Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.

P2860

Q26859193-0BBC9B3B-9302-42B9-B848-3C45BC0191E9 Q33800180-211B6D41-BAE9-476E-BB18-12462B2E584A Q33897890-0A3E243A-9A9A-4394-ABE7-B95BA4E5C578 Q34598773-D26BE79A-7F9F-4510-A956-13B8194DAC61 Q35141318-9BC2C3A6-619C-4AE1-B619-DC5E9CDE3543 Q35222202-B172ED39-39EE-4408-AD16-725FD077D45B Q35895750-B4BF847A-0942-4C24-B4A6-7CA55746FB3D Q36892008-F0F7A594-B618-4F77-81BC-D1A8CF74E138 Q37384579-0E26C847-B102-4CB2-A109-4156844B5116 Q37945102-94034CF6-2AEF-4A8E-AACE-FC3B4D843958 Q38831900-3A23EDEF-2D03-4D2B-9506-F9061C98681D Q40416580-1F11E6E4-66F2-48E5-87B5-CC672EC9A044 Q40982094-8B655FFF-DCE0-46B0-96F9-83E872F11977 Q41613604-E68B4881-D4FF-4716-B64D-275752329C7D Q42138108-6A68C464-41C8-42EB-815A-09FC2E97B93A Q46778817-CAFD8E8F-E9F9-41F3-A1B8-6B4F7EA614AD Q49184723-B3974406-CED8-4F1C-82B1-AC88445ADF03 Q55222160-DAC1C852-0F95-473F-96D6-C0F4AA81658B

P2860

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

http://www.wikidata.org/entity/Q34674995

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

@ast

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

@en

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

@nl

type

label

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

@ast

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

@en

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

@nl

prefLabel

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

@ast

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

@en

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

@nl

P1433

Q34674995-A1CEE7F3-48AD-4D0B-ADFD-BF9C450E8A31

P1476

Q34674995-47ED2268-1E6A-4FED-88CD-314D6317E453

P2093

Q34674995-222DDD10-3A91-432D-9EBD-23AC18F5DA53

Q34674995-2621517E-5109-4F29-8459-693AAC78756B

Q34674995-5E7464DD-06A2-4D17-B4A2-A0DA8122E35E

Q34674995-B7D230A5-71BB-497A-9DE7-9EB357A968A9

Q34674995-EDC68488-0F2B-49C7-8F15-A76FDDF85BF8

P2860

Q34674995-0A2ADABB-F0D0-444F-B56B-9B31EA12018E

Q34674995-11B6B9EB-8A30-408F-A065-4DB59D3DC180

Q34674995-16041841-1875-44AE-A8AA-7EE3B9D633A4

Q34674995-164151B9-C311-4DEF-9D9D-AB7AF6D78AE2

Q34674995-16FE8946-F45D-4E0E-AFFA-60E3F027A365

Q34674995-1773DD48-4D43-4B52-9CB4-29D0656CD3EA

Q34674995-1CCC2BE0-E5CE-4823-9E05-E69DE68F2BBA

Q34674995-1D8744E2-B6DF-4DB9-BD66-16AA96F5AF8B

Q34674995-39FF8477-94E1-4B58-8168-6FCC68326A72

Q34674995-431010E5-0EB8-4AE2-8CED-CD12F50DC10B

P304

Q34674995-AF8D9455-3B51-4774-BFA4-5F1831AC90A5

P31

Q34674995-5A199A5F-C490-4FAE-BCD0-CE4EC6C5A399

P356

Q34674995-D34C8373-C9EE-4709-A6F4-83B02E44913F

P433

Q34674995-90D95853-6124-4DB5-AF51-F7AACC30F907

P478

Q34674995-01CA6861-A6D8-4CBC-ACAC-41C3DE5D2F2A

P577

Q34674995-B40B9DB1-E5F1-4888-9043-96D5B8A64EEB

P5875

Q34674995-679EBE1A-B505-4E36-9528-E5E16A1165DB

P698

Q34674995-96C22D1E-0C98-465F-ACAF-338AADA75967

P921

Q34674995-9F4C2961-3D2B-4179-A002-875AA7AE94F4

P932

Q34674995-D996DC4E-A505-4973-9D73-10CCA70F6689

P356

P1433

Muscle and Nerve

P1476

Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

@en

P2093

Jennifer S Moylan

http://www.w3.org/2001/XMLSchema#string

Laura A A Gilliam

http://www.w3.org/2001/XMLSchema#string

Leigh Ann Callahan

http://www.w3.org/2001/XMLSchema#string

Marius P Sumandea

http://www.w3.org/2001/XMLSchema#string

Michael B Reid

http://www.w3.org/2001/XMLSchema#string

P2860

Purification of myeloperoxidase from equine polymorphonuclear leucocytes

Nitric oxide in skeletal muscle

Reactive oxygen in skeletal muscle. I. Intracellular oxidant kinetics and fatigue in vitro.

Physiology of nitric oxide in skeletal muscle.

4-Hydroxynonenal as a biological signal: molecular basis and pathophysiological implications.

Desmin: a major intermediate filament protein essential for the structural integrity and function of muscle.

Functional, structural, and chemical changes in myosin associated with hydrogen peroxide treatment of skeletal muscle fibers.

Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity.

Fatigue in advanced cancer: a prospective controlled cross-sectional study

Myosin essential light chain in health and disease.

P304

94-102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MUS.21809

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49695640

http://www.w3.org/2001/XMLSchema#string

P698

21171100

http://www.w3.org/2001/XMLSchema#string

P921

P932

3057655

http://www.w3.org/2001/XMLSchema#string